Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8801 to 8824 of 8900 messages
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
DateSubjectAuthorDiscuss
04/6/2020
12:22
Goes to show enormous upside potential here though.
greedy rooster
04/6/2020
12:06
CREO might not be a good direct comparison, but nevertheless the difference in figures is extraordinary. CREO revenue c£13,000 and pre-tax loss £18.6 million with marketcap £275 million: AOR revenue £470,000, loss just £0.6 million, marketcap £17.8 million. You really wonder how the market arrives at such very different valuations based on comparative figures. It's all to do with fashion, perception and presumably promotion by company brokers.
ivor hunch
04/6/2020
09:53
Don’t think creo is a comparator, however agree this is ridiculously undervalued. No value to all achieved by the company over the last year, should be at least 150m presently.
mustau
04/6/2020
08:38
As a rough comparison look at CREO - Progress on their product and a market cap of £275m. Not a buy tip but pointing to AOR being underrated.
semper vigilans
04/6/2020
08:28
...The clues are all there in that last post. They have a plan. The plan is working. The plan should deliver huge upside to patient investors!
someuwin
03/6/2020
11:37
Underpins the mockery of the current share price. Take out values have tended to be 300-500m. 'What we have is substantially more disruptive'. Nice to be sat at £18.2m market value.
greedy rooster
03/6/2020
11:23
Just posted on ProActive website: Https://www.proactiveinvestors.co.uk/companies/news/921036/aortech-chairman-eyes-a-potentially-transformational-12-to-18-months-921036.html
bones
03/6/2020
10:57
If the design of the valves is truely oustanding and the've "hit it out of the park" the'll be a queue forming soon on acquring into their portfolio. Is Bill normally reserved? as this is very high praise indeed.
nimbo10
03/6/2020
08:53
GR, agree with that. Plus, crucially, it was indicated that, following the surgical heart valve design freeze, the design teams will be straight on to the TAVR heart valve project which Bill Brown suggested would be following close behind in terms of speed to trials due to them having essentially cracked the code for manufacturing what is designed (the ideal design) rather than designing to the limitations of what it is thought can be made. Exciting indeed.
bones
03/6/2020
08:14
What I took away from the interview is once we reach design freeze on grafts and heart valve, the R&D team will start on a pipeline of new devices, probably those inherited from the RUA acquisition, which will be 'Elasteoned' - this really is turning into a disruptive tech company whose products are already required.
greedy rooster
30/5/2020
13:25
Chart du jour: free stock charts from uk.advfn.com
bones
29/5/2020
11:30
Speculating ahead (“speculating” being the word so no hanging of hats on it!), once the HV is design frozen and entered into the regulatory bench top trial (I reckon could be on that for close to a year?), might AorTech let interested parties (large OEM’s) have some samples to test themselves (concurrently) in-house, say for a couple of months, to get an idea of its capabilities? That way, they could decide to enter negotiations if their own shorter tests (on the benchtop) give outstanding data. It’s hard to imagine them not thinking that way. Just having a sample heart valve to hand should not give away any trade secrets or IP and I guess there would be stringent NDA’s signed. The recent RNS did say the prototypes are “available for evaluation” (although it didn’t say by whom). The other key factor from an industry (and AorTech) perspective will perhaps be the Primary Outcome Measure of the Foldax in-man trial due in early 2021. The hope I believe is that this is positive as it will go a long way to confirming proof of concept of polymer valves. If AorTech’s superior manufacturing system and heart valve are still developing well by that time, it’s hard to see the majors staying in the traps for much longer. They may all be racing to catch the hare! Lots of ifs and buts and much ground to cross before that scenario emerges, naturally! Speculation ends.....
bones
29/5/2020
08:04
Lots of news due between now and end of July.
someuwin
28/5/2020
21:37
I’m starting to feel sorry for patients who have received the Foldax heart valve....!
bones
28/5/2020
20:22
I tend to agree about AOR's announcements generally. There is one message for punters like me and there is another message for the likes of Edwards. Hopefully, the two messages will coincide at some point to give us a buyout of very significant proportions.
langland
28/5/2020
20:13
Like most statements from Aortech there are subtle messages for the industry in the video.The message about the heart valve having moved away from designing what can be made to making what can be designed sets them apart from Foldax who are still copying the old method of dip casting that the industry worries about.
landy90
28/5/2020
17:19
wow - yes indeed, I've also been doing my real job this afternoon, so very pleased with this.
bigwig
28/5/2020
16:32
Nice to find this higher after being out for a few hours. Mind you, I never doubted it of course...lol
langland
28/5/2020
16:29
agreed bones - great call that lol
herschel k
28/5/2020
16:22
langland 28 May '20 - 10:49 - 3549 of 3570(premium) The gap has been closed at 105 so the price can start moving up again now! Call of the week! 105p at 10.49am; 116.5p at 16.22pm
bones
28/5/2020
16:11
Must be some delayed larger trades to be declared at some point.
bones
28/5/2020
16:05
What’s the funny business with those £100 share parcels going through every minute?!
bones
28/5/2020
16:04
How much value could there be in gamechanging heart valve tech I wonder.......Edwards Q1 2020 results should inform us a bit.......oh yeah, despite Covid impacts, sales of $742 million......(so annual, assuming no further growth and Covid impacts remain (which they won't), close to $3bn)AOR market cap is just £18mLet those numbers sink in.......
herschel k
28/5/2020
16:03
Breaking out...
someuwin
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210729 07:03:40